​

Kymera Therapeutics (KYMR) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

KYMR Stock Forecast

Kymera Therapeutics (KYMR) stock forecast, based on 26 Wall Street analysts, predicts a 12-month average price target of $117.31, with a high of $138.00 and a low of $90.00. This represents a 36.19% increase from the last price of $86.14.

- $30 $60 $90 $120 $150 High: $138 Avg: $117.31 Low: $90 Last Closed Price: $86.14

KYMR Stock Rating

Kymera Therapeutics stock's rating consensus is Buy, based on 26 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 23 Buy (88.46%), 3 Hold (11.54%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 26 0 3 23 Strong Sell Sell Hold Buy Strong Buy

KYMR Price Target Upside V Benchmarks

TypeNameUpside
StockKymera Therapeutics36.19%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-335
Avg Price Target-$121.33$94.71
Last Closing Price$86.14$86.14$86.14
Upside/Downside-40.85%9.95%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 265161--22
Mar, 265171--23
Feb, 265171--23
Jan, 26518---23
Dec, 25518---23
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 26, 2026Judah FrommerMorgan Stanley$123.00$95.0329.43%42.79%
Feb 26, 2026Brian AbrahamsRBC Capital$108.00$91.8717.56%25.38%
Jan 27, 2026Eliana MerleBarclays$133.00$72.1584.34%54.40%
Dec 16, 2025RBC Capital$103.00$85.6220.30%19.57%
Dec 11, 2025Sudan LoganathanStephens$110.00$89.9022.36%27.70%
Dec 11, 2025Mizuho Securities$120.00$89.9033.48%39.31%
Dec 09, 2025Jefferies$122.00$86.8240.52%41.63%
Dec 09, 2025Srikripa DevarakondaTruist Financial$116.00$86.2734.46%34.66%
Dec 09, 2025Andrew FeinH.C. Wainwright$134.00$86.8754.25%55.56%
Dec 09, 2025Oppenheimer$120.00$85.6040.19%39.31%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 02, 2026StephensOverweightOverweighthold
Mar 02, 2026CitigroupBuyBuyhold
Feb 26, 2026Morgan StanleyOverweightOverweighthold
Feb 26, 2026RBC CapitalOutperformOutperformhold
Jan 06, 2026Wolfe ResearchEqual-WeightPeer Performdowngrade
Dec 22, 2025B. RileyBuyBuyhold
Dec 16, 2025RBC CapitalOutperformOutperformhold
Dec 11, 2025StephensOverweightOverweighthold
Dec 09, 2025JefferiesBuyBuyhold
Dec 09, 2025H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

$-9 $-8 $-7 $-6 $-5 $-4 $-3 $-2 $-1 $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.09$-2.87$-2.52$-2.98$-3.69---
Avg Forecast$-1.86$-2.90$-2.64$-2.82$-3.06$-3.54$-3.57$-2.90
High Forecast$-0.57$-0.64$-1.81$-2.15$-1.42$-2.49$-2.30$-0.03
Low Forecast$-4.13$-7.72$-3.11$-3.15$-4.14$-5.73$-4.68$-8.26
Surprise %12.37%-1.03%-4.55%5.67%20.59%---

Revenue Forecast

$0 $90M $180M $270M $360M $450M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$72.83M$46.83M$78.59M$47.07M$39.20M---
Avg Forecast$83.71M$50.19M$69.37M$53.87M$68.16M$63.62M$88.05M$181.58M
High Forecast$162.04M$114.40M$118.35M$107.40M$170.65M$64.51M$89.94M$439.66M
Low Forecast$39.15M$20.17M$39.77M$42.96M$18.28M$62.72M$86.16M$43.53M
Surprise %-12.99%-6.70%13.30%-12.62%-42.49%---

Net Income Forecast

$-500M $-400M $-300M $-200M $-100M $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-100.22M$-154.81M$-146.96M$-223.86M$-311.40M---
Avg Forecast$-78.75M$-127.85M$-146.96M$-167.47M$-162.27M$-319.20M$-203.93M$-169.39M
High Forecast$-63.00M$-102.28M$-117.57M$-125.71M$-83.08M$-145.22M$-134.43M$-1.97M
Low Forecast$-94.50M$-153.42M$-176.35M$-184.14M$-241.47M$-334.37M$-273.43M$-482.36M
Surprise %27.25%21.08%-33.67%91.90%---

KYMR Forecast FAQ

Is Kymera Therapeutics stock a buy?

Kymera Therapeutics stock has a consensus rating of Buy, based on 26 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 23 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Kymera Therapeutics is a favorable investment for most analysts.

What is Kymera Therapeutics's price target?

Kymera Therapeutics's price target, set by 26 Wall Street analysts, averages $117.31 over the next 12 months. The price target range spans from $90 at the low end to $138 at the high end, suggesting a potential 36.19% change from the previous closing price of $86.14.

How does Kymera Therapeutics stock forecast compare to its benchmarks?

Kymera Therapeutics's stock forecast shows a 36.19% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Kymera Therapeutics over the past three months?

  • April 2026: 22.73% Strong Buy, 72.73% Buy, 4.55% Hold, 0% Sell, 0% Strong Sell.
  • March 2026: 21.74% Strong Buy, 73.91% Buy, 4.35% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 21.74% Strong Buy, 73.91% Buy, 4.35% Hold, 0% Sell, 0% Strong Sell.

What is Kymera Therapeutics’s EPS forecast?

Kymera Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-3.54, marking a -4.07% decrease from the reported $-3.69 in 2025. Estimates for the following years are $-3.57 in 2027, and $-2.9 in 2028.

What is Kymera Therapeutics’s revenue forecast?

Kymera Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $63.62M, reflecting a 62.28% increase from the reported $39.2M in 2025. The forecast for 2027 is $88.05M, and $181.58M for 2028.

What is Kymera Therapeutics’s net income forecast?

Kymera Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-319M, representing an 2.50% increase from the reported $-311M in 2025. Projections indicate $-204M in 2027, and $-169M in 2028.